Protiva Biotherapeutics

Protiva Biotherapeutics

Protiva Biotherapeutics is a new biotechnology company developing a systemic non-viral gene-delivery platform. Genomics and pharmaceutical with access to novel genes require effective gene-delivery technologies to commercialize drugs. In the non-viral gene-delivery field, Protiva's technology is highly regarded as the only technology capable of generating systemically available products. Protiva will be the leader in targeted, gene-delivered protein products that are safe and effective for use in the treatment of cancer and inflammatory diseases.

Protiva was spun out of Inex Pharmaceuticals in 2001 where the technology has been under preclinical development for six years and is covered by a broad patent portfolio.

Protiva's core gene-delivery technology is referred to as 'SPLP' (Stable Plasmid Lipid Particles). Our current focus is on further developing the SPLP technology platform based on a variety of gene candidates.

Company Details

Year Established: 2000

Company Information

Mark Murray
Fax: (604) 630-5103

Products

Pharmaceuticals

Services